Based on the concept that increasing circulating ACE2 may protect against COVID-19 by occupying the cellular entry receptors on the virus, recombinant human ACE2 (rhACE2/APN01/GSK2586881) originally developed to fight other acute respiratory distress syndromes will be tested in a clinical trial to treat COVID-19 [6]. Here, ACE2 is linked to acute respiratory distress syndrome.